Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug

Genentech has put up $100 million (€88 million) in upfront and near-term milestone payments to co-develop an anti-cancer bispecific antibody with Immunocore. The deal gives the Roche subsidiary at least a partial stake in the preclinical MAGE-A4-targeting drug IMC-C103C.